Oluyemi Okupe Sells 142,886 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 142,886 shares of the firm’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $29.93, for a total transaction of $4,276,577.98. Following the completion of the transaction, the chief financial officer now owns 112,186 shares in the company, valued at $3,357,726.98. This represents a 56.02 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, October 14th, Oluyemi Okupe sold 269,739 shares of Hims & Hers Health stock. The shares were sold at an average price of $20.31, for a total transaction of $5,478,399.09.
• On Monday, October 7th, Oluyemi Okupe sold 9,868 shares of Hims & Hers Health stock. The shares were sold at an average price of $19.96, for a total value of $196,965.28.
• On Friday, September 20th, Oluyemi Okupe sold 12,651 shares of Hims & Hers Health stock. The shares were sold at an average price of $16.79, for a total value of $212,410.29.
• On Tuesday, September 3rd, Oluyemi Okupe sold 11,609 shares of Hims & Hers Health stock. The stock was sold at an average price of $14.60, for a total value of $169,491.40.

Hims & Hers Health Price Performance

Shares of HIMS traded down $6.76 during mid-day trading on Thursday, reaching $20.85. The company’s stock had a trading volume of 62,625,345 shares, compared to its average volume of 9,152,479. The company’s 50 day moving average is $19.51 and its 200 day moving average is $18.77. The stock has a market cap of $4.48 billion, a PE ratio of 49.34 and a beta of 1.06. Hims & Hers Health, Inc. has a 12-month low of $7.40 and a 12-month high of $30.44.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.06 by $0.26. The business had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company’s quarterly revenue was up 77.1% compared to the same quarter last year. During the same period last year, the firm earned ($0.04) EPS. As a group, sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Institutional Investors Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Swiss National Bank increased its holdings in Hims & Hers Health by 0.7% in the first quarter. Swiss National Bank now owns 281,500 shares of the company’s stock valued at $4,355,000 after buying an additional 2,000 shares during the last quarter. Sei Investments Co. lifted its position in Hims & Hers Health by 206.9% in the first quarter. Sei Investments Co. now owns 56,202 shares of the company’s stock worth $869,000 after purchasing an additional 37,890 shares during the period. Avantax Advisory Services Inc. acquired a new stake in shares of Hims & Hers Health during the 1st quarter valued at $156,000. ProShare Advisors LLC lifted its position in shares of Hims & Hers Health by 10.0% during the 1st quarter. ProShare Advisors LLC now owns 22,257 shares of the company’s stock valued at $344,000 after acquiring an additional 2,023 shares during the last quarter. Finally, M&G Plc acquired a new stake in shares of Hims & Hers Health during the 1st quarter valued at $8,232,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on HIMS. Imperial Capital lowered Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Needham & Company LLC initiated coverage on Hims & Hers Health in a report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price target on the stock. Canaccord Genuity Group boosted their price target on Hims & Hers Health from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. TD Cowen upped their price objective on Hims & Hers Health from $25.00 to $28.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $21.00 price objective (up from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, Hims & Hers Health has a consensus rating of “Hold” and a consensus target price of $21.21.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.